Trials / Completed
CompletedNCT02988882
OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC®)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Ocular Therapeutix, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of chronic allergic conjunctivitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexamethasone | |
| OTHER | Placebo Vehicle |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2016-04-27
- Completion
- 2016-04-27
- First posted
- 2016-12-09
- Last updated
- 2020-10-12
- Results posted
- 2018-04-30
Source: ClinicalTrials.gov record NCT02988882. Inclusion in this directory is not an endorsement.